CVE-2017-18228

Name: CVE-2017-18228
Creator: NVD / NIST
Published: 2018-03-12T23:29:00.21+00:00
License: https://creativecommons.org/publicdomain/zero/1.0/

UnknownEPSS 0.52%

Last modified Jun 17, 2026

CVE-2017-18228 is a vulnerability of currently unknown severity. Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.. EPSS estimates a 0.52% chance of exploitation in the next 30 days.

Description

Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.

Metrics

EPSS Probability

0.52%

40.2th percentile

Probability of exploitation in the next 30 days. Learn more

Weakness Enumeration

CWE-79

Affected Software

Vendor	Product	Versions
Bmc	Remedy Action Request System	<= 9.1

References

https://communities.bmc.com/thread/164169Vendor Advisory
https://communities.bmc.com/thread/164169Vendor Advisory

Timeline

Published: Mar 12, 2018
Last Modified: Jun 17, 2026
Status: Modified

Frequently Asked Questions

What is CVE-2017-18228?

Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.

How severe is CVE-2017-18228?

Severity scoring for CVE-2017-18228 is pending analysis. The EPSS model estimates a 0.52% probability of exploitation in the next 30 days.

How do I fix CVE-2017-18228?

Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.

Are you affected by CVE-2017-18228?

Run a free Strix scan to check your systems for this vulnerability.

Scan your code now

Source: NVD / NIST